Research programme: cell therapies - ViaCell

Drug Profile

Research programme: cell therapies - ViaCell

Latest Information Update: 06 Apr 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ViaCell
  • Developer Amgen; ViaCell
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Heart failure; Muscular dystrophies; Stroke

Most Recent Events

  • 08 Sep 2008 Preclinical development is ongoing in USA
  • 09 Sep 2005 Preclinical data from a media release have been added to the Heart failure pharmacodynamics section
  • 30 Mar 2005 Preclinical trials in Heart failure in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top